Holen Sie sich die Stockscreener-App
47.87
2.37%
-1.16
Handel nachbörslich:
48.02
0.15
+0.31%
Schlusskurs vom Vortag:
$49.03
Offen:
$47.6
24-Stunden-Volumen:
1.16M
Relative Volume:
6.68
Marktkapitalisierung:
$339.42M
Einnahmen:
$56.54M
Nettoeinkommen (Verlust:
$-30.70M
KGV:
-122.74
EPS:
-0.39
Netto-Cashflow:
$-31.05M
1W Leistung:
-2.96%
1M Leistung:
+111.21%
6M Leistung:
+75.35%
1J Leistung:
+301.26%
1-Tages-Spanne:
$44.46
$48.76
1-Wochen-Bereich:
$44.46
$51.46
52-Wochen-Spanne:
$10.14
$56.83
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Firmenname
Cidara Therapeutics Inc
Sektor
Branche
Telefon
858-752-6170
Adresse
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Vergleichen Sie CDTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
47.87 | 339.42M | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-12 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-27 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-08 | Eingeleitet | Guggenheim | Buy |
| 2024-08-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-09-22 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-07-26 | Eingeleitet | Citigroup | Buy |
| 2017-04-21 | Eingeleitet | Raymond James | Strong Buy |
| 2017-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-04-11 | Fortgesetzt | Wedbush | Outperform |
| 2017-02-22 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-22 | Hochstufung | WBB Securities | Sell → Hold |
| 2016-12-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-09-23 | Herabstufung | WBB Securities | Hold → Sell |
| 2015-10-09 | Hochstufung | WBB Securities | Sell → Hold |
| 2015-05-11 | Eingeleitet | Jefferies | Buy |
| 2015-05-11 | Eingeleitet | Leerink Partners | Outperform |
| 2015-05-11 | Eingeleitet | Needham | Buy |
| 2015-05-11 | Eingeleitet | Wedbush | Outperform |
| 2015-04-23 | Eingeleitet | WBB Securities | Sell |
Alle ansehen
Cidara Therapeutics Inc Aktie (CDTX) Neueste Nachrichten
(CDTX) Proactive Strategies - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Receives Buy Rating from HC Wainwrigh - GuruFocus
H.C. Wainwright assumes coverage on Cidara stock with buy rating By Investing.com - Investing.com UK
H.C. Wainwright Initiates Coverage on Cidara Therapeutics (CDTX) with Strong Outlook | CDTX Stock News - GuruFocus
Cidara Therapeutics (NASDAQ:CDTX) Given Overweight Rating at Cantor Fitzgerald - Defense World
Cidara Therapeutics (CDTX) Reiterates Overweight Rating by Canto - GuruFocus
(CDTX) Investment Analysis - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Holdings in Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
Cidara Therapeutics stock maintains strong rating at Citizens JMP By Investing.com - Investing.com Canada
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $36.00 at Needham & Company LLC - Defense World
Insider Buying: Chrysa Mineo Acquires Shares of Cidara Therapeutics Inc (CDTX) - GuruFocus
Needham raises Cidara Therapeutics stock price target to $36 - Investing.com
Cidara Therapeutics (CDTX) Price Target Raised by Needham | CDTX Stock News - GuruFocus
Cidara Therapeutics (NASDAQ:CDTX) Given Market Outperform Rating at JMP Securities - Defense World
Cidara Therapeutics (CDTX) Maintains Market Outperform Rating | CDTX Stock News - GuruFocus
12,714 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Purchased by Jane Street Group LLC - Defense World
Northern Trust Corp Has $913,000 Stock Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals - Value The Markets
Cidara Therapeutics (NASDAQ:CDTX) Given “Market Outperform” Rating at JMP Securities - Defense World
JMP Securities Reiterates Market Outperform Rating for Cidara Therapeutics (CDTX) | CDTX Stock News - GuruFocus
Cidara stock target holds at $47 by JMP on trial confidence - Investing.com Canada
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Analysts - Defense World
(CDTX) On The My Stocks Page - news.stocktradersdaily.com
Cidara Therapeutics: All Stars Aligning In Favor Of CD388 (NASDAQ:CDTX) - Seeking Alpha
Royal Bank of Canada Increases Cidara Therapeutics (NASDAQ:CDTX) Price Target to $35.00 - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Earns Buy Rating from Needham & Company LLC - Defense World
Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS) - The Globe and Mail
Cidara Therapeutics (CDTX) Receives Price Target Upgrade from RB - GuruFocus
Cidara Therapeutics (CDTX) Receives Price Target Upgrade from RBC Capital | CDTX Stock News - GuruFocus
RBC Capital Ups Price Target for Cidara Therapeutics (CDTX) Amid Optimism | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX): Analyst Reiterates Buy Rating | CDTX Stock News - GuruFocus
RBC Raises Price Target on Cidara Therapeutics to $35 From $31, Keeps Outperform, Speculative Risk - marketscreener.com
Transcript : Cidara Therapeutics, Inc.Special Call - marketscreener.com
Seasonal Influenza Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis - Barchart.com
Seasonal Influenza Market to Reach New Heights in Growth by 2034, - openPR.com
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
CDTX Stock Price and Chart — NASDAQ:CDTX - TradingView
When (CDTX) Moves Investors should Listen - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Target Price Raised by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenh - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics price target raised to $50 from $35 at Guggenheim - TipRanks
Cidara Therapeutics to Host Virtual R&D Day to Discuss - GlobeNewswire
Revolutionary Once-Per-Year Universal Flu Prevention: Cidara Unveils Phase 2b Trial Updates at R&D Day - Stock Titan
Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 - The Manila Times
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Cidara Therapeutics’ CD388 Progress and Challenges Highlighted in Earnings Call - MSN
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $35.00 - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, JMP Securities Analyst Says - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Guggenheim Raises Price Target for Cidara Therapeutics (CDTX) to $35.00 | CDTX Stock News - GuruFocus
Finanzdaten der Cidara Therapeutics Inc-Aktie (CDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cidara Therapeutics Inc-Aktie (CDTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mineo Chrysa | Director |
Jun 02 '25 |
Buy |
21.71 |
2,270 |
49,281 |
2,270 |
| Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
| Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
| Sandison Taylor | Chief Medical Officer |
Sep 11 '24 |
Sale |
11.64 |
924 |
10,752 |
23,067 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):